BCL2 and acute lymphoblastic leukemia: Consistent with this, we found remarkably high BCL-2 mRNA (Fig. 2A) and protein expression levels (Fig. 2B+C) as compared to other venetoclax-sensitive (VENsens) or -insensitive (VENins) BCP-ALL cell lines and primary ALL patient-derived xenograft samples (PDX) (Fig. 2D).